Company Information
CIN
Status
Date of Incorporation
14 June 2004
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 September 2023
Paid Up Capital
19,681,000
Authorised Capital
20,000,000
Directors
Piyush Bhailal Shah
Director/Designated Partner
over 2 years ago
over 2 years ago
Deepak Bhailal Shah
Director/Designated Partner
about 13 years ago
about 13 years ago
Past Directors
Hiromi Deepak Shah
Whole Time Director
about 13 years ago
about 13 years ago
Bhailal Babulal Shah
Whole Time Director
about 13 years ago
about 13 years ago
Virendra Babulal Shah
Director
about 20 years ago
about 20 years ago
Patents
The present invention discloses an Orlistat composition which has an averages particle size of pellets of not less than or equal to 2mm and is devoid of microcrystalline cellulose. The invention further discloses a process for manufacturing thereof.
The present invention discloses a pharmaceutical formulation for treatment of benzimidazole induced hypomagnesaemia. The formulation of the invention contains a therapeutically effective amount of benzimidazole and therapeutically effective amount of dietary Magnesium source. The invention further relates to a proce...
The present invention discloses a novel stable formulation for D-enantiomer of
rabeprazole containing a primary amine as stabilizing agent and process for manufacturing thereof.
Novel acid resistant pharmaceutical composition of Duloxetine comprises
Hydroxypropyl methyl Cellulose Trimellitate (HPMCT) as an enteric polymer and a process for manufacturing thereof.
The present invention relates to a novel Cilostazol composition. More particularly, the invention relates to a novel sustained release formulation of Cilostazol, which is essentially devoid of any release controlling agent, and the process for formulation thereof.
Galantamine extended release pellets / particles /beads and the like and the process for preparing the formulation wherein the release is extended by the Dual retard technique imparted by the Galantamine Hydrobromide - Glyceryl behenate Complex obtained by the hot melt process and further by the extended release coa...
The invention relates to a method of preparation of an instant release oral solid dosage form of an insoluble 5α-reductase inhibitor and pharmaceutical preparations containing thereof particularly in the form of drug coated non pareil seeds or pellets or beads comprising the active.
Aspects of the present disclosure relate to controlled release formulation comprising at least one substituted benzimidazole derivative, which in operation can provide effective plasma concentration thereof to a subject in need of a treatment over an extended period of time. An aspect of the present disclosure provi...
ABSTRACT
A METHOD FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITION OF LEVOTHYROXINE ORAL SOLUTION
The present invention relates to a method for the preparation of pharmaceutical composition of levothyroxine oral solution. The present invention is in particular about the method of preparing stable pharmaceutic...
Controlled release pharmaceutical composition of mirabegron
The present invention relates to a controlled release pharmaceutical composition of mirabegron comprising mirabegron or a pharmaceutically acceptable salt thereof and a non hydrogel-forming excipient selected from glycerol dibehenate, ethyl cellulose, ce...
Pharmaceutical composition of docusate and process for preparation thereof
The present invention relates to a pharmaceutical composition of docusate and process for its preparation. The pharmaceutical composition optionally further comprises sennosides. The pharmaceutical composition of the present invention is pre...
Extended release pharmaceutical composition of mirabegron
The present invention relates to an extended release pharmaceutical composition of mirabegron comprising mirabegron or a pharmaceutically acceptable salt thereof, polyethylene glycol having an average molecular weight of 1,800 to 9,000, polyethylene oxide ha...
Registered Trademarks
[Class : 5] Capsules (Medicinal Preparation)
[Class : 5] Medicinal & Pharmaceutical Preparations
[Class : 5] Medicinal Preparation
View +3 more Brands for Titan Laboratories Private Limited.
Charges
01 October 2014
The Ratnakar Bank Limited
3 Crore
22 August 2014
Rbl Bank Limited
29 Crore
22 May 2013
Rbl Bank Limited
28 Crore
25 September 2009
Unoon Bank Of India
95 Lak
13 March 2009
Union Bank Of India
25 Lak
05 August 2005
Union Bank Of India
6 Crore
19 April 2005
Union Bank Of India
40 Lak
19 April 2005
Union Bank Of India
3 Crore
27 January 2005
The N.k.g.s.b. Co-op. Bank Ltd.
9 Lak
16 January 2020
Rbl Bank Limited
7 Crore
06 January 2023
Others
0
06 January 2023
Others
0
22 May 2013
Others
0
16 January 2020
Others
0
22 August 2014
Others
0
01 October 2014
The Ratnakar Bank Limited
0
27 January 2005
The N.k.g.s.b. Co-op. Bank Ltd.
0
19 April 2005
Union Bank Of India
0
19 April 2005
Union Bank Of India
0
13 March 2009
Union Bank Of India
0
25 September 2009
Unoon Bank Of India
0
05 August 2005
Union Bank Of India
0
06 January 2023
Others
0
06 January 2023
Others
0
22 May 2013
Others
0
16 January 2020
Others
0
22 August 2014
Others
0
01 October 2014
The Ratnakar Bank Limited
0
27 January 2005
The N.k.g.s.b. Co-op. Bank Ltd.
0
19 April 2005
Union Bank Of India
0
19 April 2005
Union Bank Of India
0
13 March 2009
Union Bank Of India
0
25 September 2009
Unoon Bank Of India
0
05 August 2005
Union Bank Of India
0
06 January 2023
Others
0
06 January 2023
Others
0
22 May 2013
Others
0
16 January 2020
Others
0
22 August 2014
Others
0
01 October 2014
The Ratnakar Bank Limited
0
27 January 2005
The N.k.g.s.b. Co-op. Bank Ltd.
0
19 April 2005
Union Bank Of India
0
19 April 2005
Union Bank Of India
0
13 March 2009
Union Bank Of India
0
25 September 2009
Unoon Bank Of India
0
05 August 2005
Union Bank Of India
0
Documents
Form DPT-3-06082020-signed
Form MGT-14-07072020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-07072020
Evidence of cessation;-27052020
Form DIR-12-27052020_signed
Notice of resignation;-27052020
Instrument(s) of creation or modification of charge;-21012020
Optional Attachment-(2)-21012020
Form CHG-1-21012020_signed
Optional Attachment-(1)-21012020
CERTIFICATE OF REGISTRATION OF CHARGE-20200121
Form AOC-4(XBRL)-11112019_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-06112019
Optional Attachment-(1)-06112019
Copy of MGT-8-05112019
List of share holders, debenture holders;-05112019
Form MGT-7-05112019_signed
Form DPT-3-28062019
Form MSME FORM I-10062019_signed
Instrument(s) of creation or modification of charge;-15042019
Form CHG-1-15042019_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20190415
Instrument(s) of creation or modification of charge;-01122018
Form CHG-1-01122018_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20181201
List of share holders, debenture holders;-08102018
Directors report as per section 134(3)-08102018
Copy of MGT-8-08102018
Form AOC-4-08102018_signed
Form MGT-7-08102018_signed
